Evidence map›Paper›PMID 26376680›Full record

SynthesisOncotarget2015

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.

Tengfei Zhang, Ling Cao, Jing Xie, Ni Shi, Zhen Zhang, Zhenzhen Luo, Dongli Yue, Zimeng Zhang, Liping Wang, Weidong Han and 3 more

Open access · diamondAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 10 pooled it
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 10 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. The growing world of CAR T cell trials: a systematic review.Cancer immunology, immunotherapy : CII · 2016
    Pooled it
  10. Pooled it
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Tengfei ZhangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ling CaoBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jing XieCenter for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia.
Ni ShiComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Zhen ZhangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhenzhen LuoBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Dongli YueBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zimeng ZhangDepartment of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Liping WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Weidong HanMolecular & Immunological/Bio-Therapeutic Department, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, China.
Zhongwei XuDepartment of Gastroenterology, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Hu ChenDepartment of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Science, Beijing, China.
Yi ZhangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CNAcademy of Military Medical Sciences · CNCentre for Eye Research Australia · AUChinese PLA General Hospital · CNHarvard University · USPennsylvania Hospital · USThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) modified T cells targeted CD19 showed promising clinical outcomes in treatment of B cell malignances such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and other indolent lymphomas. However, the clinical benefit varies tremendously among different trials. This meta-analysis investigated the efficacy (response rates and survival time) of CD19-CAR T cells in refractory B cell malignances in Phase I clinical trials. We searched publications between 1991 and 2014 from PubMed and Web of Science. Pooled response rates were calculated using random-effects models. Heterogeneity was investigated by subgroup analysis and meta-regression. Fourteen clinical trials including 119 patients were eligible for response rate evaluation, 62 patients in 12 clinical trials were eligible for progression-free survival analysis. The overall pooled response rate of CD19-CAR T cells was 73% (95% confidence interval [CI]: 46-94%). Significant heterogeneity across estimates of response rates was observed (p < 0.001, I2=88.3%). ALL patients have higher response rate (93%, 95% CI: 65-100%) than CLL (62%, 95% CI: 27-93%) and lymphoma patients (36%, 95% CI: 1-83%). Meta-regression analysis identified lymphodepletion and no IL-2 administrated T cells as two key factors associated with better clinical response. Lymphodepletion and higher infused CAR T cell number were associated with better prognosis. In conclusion, this meta-analysis showed a high clinical response rate of CD19-CAR T cell-based immunotherapy in treatment of refractory B cell malignancies. Lymphodepletion and increasing number of infused CD19-CAR T cells have positive correlations with the clinical efficiency, on the contrary, IL-2 administration to T cells is not recommended.

Indexed as

Antigens, CD19Clinical Trials, Phase I as TopicDisease-Free SurvivalFemaleHumansImmunotherapy, AdoptiveInterleukin-2Leukemia, Lymphocytic, Chronic, B-CellLymphomaMalePrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisProportional Hazards ModelsReceptors, Antigen, T-CellRegression AnalysisRemission InductionAntigens, CD19Interleukin-2Receptors, Antigen, T-CellB cell malignanciesCD19chimeric antigen receptorefficiencymeta analysis

Identifiers

PMID26376680
PMCPMC4741817
OpenAlexW2112359076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.